Applied Molecular Transport to Present at Jefferies Next Generation IBD Therapeutics Virtual Summit
2020年9月22日 - 9:00PM
Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage
biopharmaceutical company, today announced that Tahir Mahmood,
Ph.D., chief executive officer and co-founder of AMT, and Bittoo
Kanwar, M.D., chief medical officer of AMT, will participate in a
fireside chat during the Jefferies Next Generation IBD Therapeutics
Virtual Summit which will be webcasted on Wednesday, September 23,
2020 at 8:00 a.m. ET.
The webcast will be accessible via the Events page of the
Applied Molecular Transport website at
https://ir.appliedmt.com/news-events/events. An archived replay
will be available for 30 days following the event.
About Applied Molecular Transport Inc.Applied
Molecular Transport Inc. is a clinical-stage biopharmaceutical
company leveraging its proprietary technology platform to design
and develop a pipeline of novel oral biologic product candidates to
treat autoimmune, inflammatory, metabolic, and other diseases.
AMT’s proprietary technology platform allows it to exploit existing
natural cellular trafficking pathways to facilitate the active
transport of diverse therapeutic modalities across the intestinal
epithelium (IE) barrier. Active transport is an efficient mechanism
that uses the cell’s own machinery to transport materials across
the IE barrier. AMT believes that its ability to exploit this
mechanism is a key differentiator of its approach. AMT is
developing oral biologic product candidates in patient-friendly
tablet and capsule forms that are designed for either targeting
local gastrointestinal (GI) tissue or entering systemic circulation
to precisely address the relevant biology of a disease. AMT is
building a portfolio of oral product candidates based on its
technology platform including its lead product candidate, AMT-101,
an oral GI-selective interleukin 10 that has completed a Phase 1b
clinical trial in patients with ulcerative colitis (UC). AMT
further plans to initiate Phase 2 clinical trials of AMT-101 in UC
and related inflammatory indications. AMT’s technology platform
enables it to design and develop various oral biologic therapeutic
modalities, such as peptides, proteins, full-length antibodies,
antibody fragments, and RNA therapeutics, with potentially
significant advantages over existing marketed and development-stage
drugs.
Contacts:Sylvia WheelerPrincipal, Wheelhouse
Life Science Advisorsswheeler@wheelhouselsa.com
Alexandra SantosSenior Partner, Wheelhouse Life Science
Advisorsasantos@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
過去 株価チャート
から 6 2024 まで 7 2024
Applied Molecular Transp... (NASDAQ:AMTI)
過去 株価チャート
から 7 2023 まで 7 2024